Averbukh L A
Antibiotiki. 1977 Dec;22(12):1103-11.
Two sublines of mouse lymphadenosis (L-5178) resistant to bruneomycin and rubomycin used alone, as well as a subline with induced resistance to the combination of these drugs were employed in the study. The studies showd that in separate use of rubomycin and bruneomycin the tumor cell resistance to the respective drug was evident at the 10th passage. After 30 passages neither bruneomycin nor rubomycin produced reliable inhibition of the tumor growth in the respective subline of lyphadenosis. When the antibiotics were used in combination, no significant decrease in sensitivity of the tumor cells to either of the drugs or their combination was observed. The experiment with Staph. aureus also showed that the rate of the resistance increase to the drug combination was lower than that to the drugs used alone. Therefore, it was shown that the combined use of bruneomycin and rubomycin provided a means for preventing to a significant extent of development of the resistance in lymphadenosis tumor cells and Staph. aureus. This may be considered as an indication for clinical trials of the above combination.
本研究采用了对单独使用的布鲁诺霉素和柔红霉素耐药的两株小鼠淋巴腺病（L-5178）亚系，以及对这两种药物联合使用具有诱导抗性的一个亚系。研究表明，在单独使用柔红霉素和布鲁诺霉素时，肿瘤细胞对相应药物的抗性在第10代时就很明显。30代后，布鲁诺霉素和柔红霉素均未对淋巴腺病的相应亚系肿瘤生长产生可靠的抑制作用。当联合使用抗生素时，未观察到肿瘤细胞对任何一种药物或其组合的敏感性有显著降低。对金黄色葡萄球菌的实验也表明，对药物组合的抗性增加速率低于单独使用药物时。因此，表明布鲁诺霉素和柔红霉素的联合使用为在很大程度上预防淋巴腺病肿瘤细胞和金黄色葡萄球菌中抗性的发展提供了一种手段。这可被视为上述组合进行临床试验的一个指征。
